Advertisement

Topics

Genentech, Inc. Company Profile

17:24 EDT 21st September 2017 | BioPortfolio

Founded more than 35 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California.

Research
Genentech conducts basic and applied research in the areas of in Oncology, Immunology, Neuroscience, Metabolism, and Infectious Disease. Genentech's approximately 1,200 researchers and scientists and 135 postdocs consistently publish important papers in prestigious journals and are among the total citations.

Pipeline
Genentech's development pipeline continues to grow, with multiple promising projects in the following therapeutic focus areas: Oncology, Immunology, Neuroscience, Metabolism, and Infectious Disease. Genentech's clinical development pipeline includes monoclonal antibodies, small molecules, and antibody drug conjugates that address serious unmet medical needs.

Key Products
Since the company was founded in 1976, Genentech has focused its drug discovery efforts on medicines that address significant unmet medical needs. Today Genentech has multiple products on the market for serious or life-threatening medical conditions. In March 2009, Genentech became a member of the Roche Group, and Genentech now serves as the headquarters for all Roche pharmaceutical operations in the United States. Accordingly, the list below includes products, which were previously marketed as Roche products that are now being marketed by Genentech in the United States.

BIOONCOLOGY
Avastin® (bevacizumab)
Erivedge® (vismodegib)
Herceptin® (trastuzumab)
Kadcyla™ (ado-trastuzumab emtansine)
Perjeta® (pertuzumab)
Rituxan® (rituximab-BioOncology)
Tarceva® (erlotinib)
Xeloda® (capecitabine)
Zelboraf® (vemurafenib)

IMMUNOLOGY AND OPHTHALMOLOGY
Actemra® (tocilizumab)
Lucentis™ (ranibizumab injection)
Rituxan® (rituximab - Immunology)
Xolair® (omalizumab)

METABOLISM & PRIMARY CARE
Activase® (alteplase)
Cathflo Activase® (alteplase)
Nutropin AQ® (somatropin (rDNA origin) for injection)
TNKase® (tenecteplase)

VIROLOGY & SPECIALTY CARE
CellCept® (mycophenolate mofetil)
Pegasys® (peginterferon alfa-2a)
Pulmozyme® (dornase alfa)
Tamiflu® (oseltamivir phosphate)
Valcyte® (valganciclovir hydrochloride)

OTHER PRODUCTS
Anaprox® (naproxen sodium)
Boniva Injection® (ibandronate sodium)
Boniva Tablets® (ibandronate sodium)
Cytovene® (ganciclovir)
EC-Naprosyn® (naproxen)
Fuzeon® (enfuvirtide)
Invirase® (saquinavir mesylate)
Klonopin® (clonazepam)
Kytril Injection™ (granisetron HCL)
Kytril Tablets® (ganisetron HCL)
Naprosyn® (naproxen)
Rocephin® (ceftriaxone)
Roferon-A® (interferon alfa-2a)
Romazicon® (flumazenil)
Valium ® (diazepam)
Xenical® (orlistat)
Zenapax® (daclizumab)

Source: http://www.gene.com/medical-professionals/medicines

Location

1 DNA Way
South San Francisco
CA
94080
USA

Contact

Phone: (650) 225-1000
Fax: (650) 225-6000


News Articles [183 Associated News Articles listed on BioPortfolio]

Genentech BD: Alzheimer's continues to be a priority

Genentech's Tom Zioncheck sat down with BioPharma Dive to talk about the big biotech's work in Alzheimer's disease. 

Genentech gets FDA nod for Actemra

Genentech's Actemra, or tocilizumab, which is indicated for the treatment of patients with CAR-T cell-induced cytokine releas -More- 

Genentech Drug Fails to Beat Chemo in Treating Advanced Bladder Cancer

Genentech’s hopes to expand applications of a cancer immunotherapy treatment to more cancers were dealt a blow with the failure of that drug in a late-stage clinical trial. South San Francisco, CA-b...

Genentech recalls lots of Activase due to lack of sterility assurance

Genentech, a subsidiary of Swiss pharma giant Roche, is voluntarily recalling three lots of Activase…

Exelixis and Genentech hammer out new deal terms

After a year of arbitration, Exelixis and Genentech shake hands on a revised deal.

Genentech Returns Cancer Drug Rights to NewLink

US biotechnology group Genentech, part of Roche, is handing back rights to NewLink Genetics’ IDO inhibitor GDC-0919 (navoximod), an investigational cancer treatment. Genentech gained rights to n...

FDA grants Priority Review for Genentech’s Gazyva

Genentech, a member of the Roche Group, announced that the FDA has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Gazyva (obinutuzumab) in ...

Genentech’s Actemra FDA approved for giant cell arteritis

Genentech, a member of the Roche Group, announced that the FDA has approved Actemra (tocilizumab) subcutaneous injection for the treatment of giant cell arteritis (GCA), a chronic and severe autoimmun...

Drugs and Medications [12 Associated Drugs and Medications listed on BioPortfolio]

Boniva [Genentech, Inc.]

These highlights do not include all the information needed to use BONIVA Tablets safely and effectively. See full prescribing information for BONIVA Tablets. BONIVA (ibandronate sodium) Tablets Initia...

Copegus [Genentech, Inc.]

These highlights do not include all the information needed to use COPEGUS safely and effectively. See full prescribing information for COPEGUS. COPEGUS (ribavirin) Tablets Initial U.S. Approval: 2002

Pegasys [Genentech, Inc.]

These highlights do not include all the information needed to use PEGASYS safely and effectively. See full prescribing information for PEGASYS. PEGASYS® (peginterferon alfa-2a)Injection for Subcutan...

Boniva [Genentech, Inc.]

BONIVA (ibandronate sodium) INJECTION

Pulmozyme [Genentech, Inc.]

Pulmozyme (dornase alfa)Inhalation Solution

PubMed Articles [9 Associated PubMed Articles listed on BioPortfolio]

Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases With Non-Response to Bevacizumab.

To study the effect of early switching to ranibizumab (Lucentis; Genentech, South San Francisco, CA) or aflibercept (Eylea; Regeneron, Tarrytown, NY) in cases of diabetic macular edema (DME) that have...

Genentech's Ocrevus heralds new chapter in MS treatment.

Expression of MET in circulating tumor cells correlates with expression in tumor tissue from advanced-stage lung cancer patients.

Given the difficulty in obtaining adequate tissue in NSCLC, we investigated the utility of circulating tumor cells (CTCs) for MET status assessment in NSCLC patients. We used two platforms for CTC cap...

Pre-Existing RPE Atrophy and Defects in the External Limiting Membrane Predict Early Poor Visual Response to Ranibizumab in Neovascular Age-Related Macular Degeneration.

The aim of this study was to identify the rate of early visual acuity poor responders in patients with neovascular age-related macular degeneration (AMD) after the first intravitreal injection of rani...

Fluorescein Angiography Versus Optical Coherence Tomography Angiography in Macular Telangiectasia Type I Treated With Bevacizumab Therapy.

This is a report of microvascular changes seen on fluorescein angiography (FA) and optical coherence tomography angiography (OCTA) in a 47-year-old man with macular telangiectasia Type 1 (MacTel1) aft...

Clinical Trials [35 Associated Clinical Trials listed on BioPortfolio]

Mechanisms of Exacerbation of Asthma

The purpose of this study is to identify the causes of asthma that were not previously suspected, to better understand the effects of inhaled steroids on asthma and to identify new way to ...

Study of the Mechanisms of Asthma

The purpose of this study is to identify the causes of asthma that were not previously suspected, to better understand the effects of inhaled steroids on asthma and to identify new way to ...

A Study of GDC-0449 (Hedgehog Pathway Inhibitor) in Patients Treated With GDC-0449 in a Previous Genentech-Sponsored Phase I or II Cancer Study

This is a multicenter, open-label extension study. Patients receiving GDC-0449 in a Genentech-sponsored study who have completed the parent study or who continue to receive GDC-0449 at th...

An Extension Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study

This is a multicenter, open-label extension study. Subjects who have received rhuMAb VEGF (Avastin) therapy in any Genentech-sponsored Phase I or Phase II cancer study and who did not sho...

An Extension Study to Provide Continued Avastin Therapy to Patients With Solid Tumours Who Were Previously Enrolled in a Roche/Genentech Sponsored Study

This single-arm, open-label, multicentre extension study will provide continued Avastin [bevacizumab] therapy to patients with solid tumours who were previously enrolled in a Roche/Genente...

Companies [41 Associated Companies listed on BioPortfolio]

VaxGen Incorporated

VaxGen were formed to continue development of AIDSVAX in partnership with Genentech. In connection with our formation, Genentech licensed to us the technology necessary for completing development and ...

Genentech, Inc.

Founded more than 35 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening me...

Genentech

Considered the founder of the biotechnology industry, Genentech has been delivering on the promise of biotechnology for more than 30 years, using human genetic information to discover, develop, commer...

Lpath

Lpath, Inc., headquartered in San Diego, California, is a theranostics company focused on bioactive signaling lipids as targets for treating and diagnosing important human diseases. Lpath's lead produ...

ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agent...

More Information about "Genentech, Inc." on BioPortfolio

We have published hundreds of Genentech, Inc. news stories on BioPortfolio along with dozens of Genentech, Inc. Clinical Trials and PubMed Articles about Genentech, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Genentech, Inc. Companies in our database. You can also find out about relevant Genentech, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record